{
    "nct_id": "NCT06650163",
    "official_title": "Biologic Validation of Zr-89 Crefmirlimab Berdoxam CD8+ Minibody ImmunoPET in Human Brain Tumors",
    "inclusion_criteria": "* Male or female >= 18 years of age\n* Documentation of a diagnosis of brain tumor including brain metastases, any grade of gliomas and meningiomas\n* The participant is scheduled for standard of care surgical tumor resection\n* The participant (or legally acceptable representative if applicable) provides written informed consent for the trial\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Male or female < 18 years of age\n* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data\n* Not medically cleared for surgery\n* Individuals who cannot tolerate MRI scan or PET/CT scan\n* Pregnant or breast-feeding women\n* Serum creatinine OR measured or calculated creatinine clearance (Glomerular filtration rate [GFR] can be use in place of creatinine or creatinine clearance [CrCl]) =< 1.5 X institutional upper limit of normal (ULN) OR >= 60mL/min for subjects with creatinine levels > 1.5 X institutional ULN\n\n  * Creatinine clearance should be calculated per institutional standard\n* Serum total bilirubin: =< 1.5 X institutional ULN OR direct bilirubin =< institutional ULN for subjects with total bilirubin levels > 1.5 institutional ULN\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X institutional ULN OR =< 5 X institutional ULN for subjects with Gilberts syndrome\n* Albumin >= 2.5 mg/dL\n* Patients with splenic dysfunction or post splenectomy\n* Any abnormalities that would be a contraindication to gadolinium-based contrast agent",
    "miscellaneous_criteria": ""
}